Our mission is to create a world without lupus, and the voices of our advocates are one of the most powerful tools we have. Together with our advocates, we have pushed forward massive policy change ...

The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

Black History Month is a time to honor the strength, resilience, and contributions of the Black community. This year, we’re focusing on the theme “Your Voice, Your Power” to highlight the importance ...

The way we talk about lupus – to ourselves and with others – matters. Living with lupus can feel like a daily battle filled with uncertainty. Negative self-talk about this disease and its limitations ...